Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Schizophr Res. 2016 Feb 11;177(1-3):78–87. doi: 10.1016/j.schres.2016.01.054

Figure 5. Protein palmitoylation is not affected by chronic antipsychotic treatment.

Figure 5

Rats treated for 9 months with haloperidol decanoate did not exhibit changes in palmitoylation, suggesting that decreased palmitoylation in schizophrenia is not likely due to antipsychotic treatment. ABE assay and western blotting were used to quantify protein palmitoylation in rat frontal cortex. A) Palmitoylation of proteins was analyzed by measuring intensity of biotinylation of proteins within sixteen bands representing palmitoylated-proteins of different molecular weights. B) Representative western blots probed with streptavidin and PSD-95 from haloperidol (H) and vehicle (C) treated rats.

C) Biotinylation levels of proteins within each of the rectangles were normalized to expression of PSD-95 present in each sample. Data are presented as the ratio of palmitoylation in frontal cortex from rats treated with haloperidol decanoate divided by values from control rats for each molecular weight band with means ± SEM overlayed. For no bands were there significant differences in palmitoylation between vehicle and haloperidol treated animals.